Identifying Factors of Organoid Establishment in Pancreatic Cancer: A Prospective Observational Study
In this prospective observational trial, we show that PDO generation is feasible at a success rate of 58% within a clinically reasonable time frame of 6 weeks. The efficacy of PDO establishment depended on sample site, with metastatic samples showing higher establishment rates. Higher CA 19-9 levels were positively correlated with PDO growth. Successful PDO establishment did not have a prognostic value for OS. Overall, our findings underline the great potential of PDO-based precision medicine approaches, which should further be evaluated in prospective interventional translational trials.
Authors
- Uwe Pelzer (ORCID: https://orcid.org/0000-0001-9213-2737)
- S. Stintzing
- Marcus Bahra
- Markus Herbert Lerchbaumer (ORCID: https://orcid.org/0000-0003-1151-9935)
- Anna Luisa Kühn (ORCID: https://orcid.org/0000-0001-9512-9461)
- C. Neumann
- F Schneider (ORCID: https://orcid.org/0000-0002-1452-7562)
- Gregor Duwe (ORCID: https://orcid.org/0000-0001-7008-1238)
- Georg Hilfenhaus (ORCID: https://orcid.org/0000-0001-8764-077X)
- Ulrich Keilholz (ORCID: https://orcid.org/0000-0001-6773-9406)
- Dragomir Mihnea-Paul
- Loredana Vecchione (ORCID: https://orcid.org/0000-0003-3942-5498)
- Christian Jürgensen (ORCID: https://orcid.org/0000-0002-0540-822X)
- Katharina Wansch
- Florian Dölvers
- Reinhold Schäfer
- Maria Joosten
- Matthäus Felsenstein
Institutions
- German Cancer Research Center (DE)
- Johannes Gutenberg University Mainz (DE)
- Heidelberg University (DE)
- Humboldt-Universität zu Berlin (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Krankenhaus Waldfriede (DE)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-12-30
- DOI
- https://doi.org/10.1002/cam4.71490
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Deutschen Konsortium für Translationale Krebsforschung
- Berlin Institute of Health